Á¦ 51Â÷ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãß°è±¹Á¦Çмú´ëȸ : 2019-11-09±³À°ÀÏÀÚ : 2019-11-09
±³À°Àå¼Ò : ¼¿ï, ÄÜ·¡µåÈ£ÅÚ(¿©Àǵµ) ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
Á¦ 51Â÷ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãß°è±¹Á¦Çмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : Á¤º°
¿¬¶ôó : 02-565-3350
À̸ÞÀÏ :
ksh@koreanhypertension.org ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, ½Å°æ¿Ü°ú, ½Å°æ°ú, °¡Á¤ÀÇÇаú¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í *»çÀüµî·Ï: Á¤È¸¿ø(6¸¸¿ø),Á¤È¸¿ø ¿Ü(8¸¸¿ø), Àü°øÀǹױâŸ(4¸¸¿ø), °£È£»ç/¿µ¾ç»ç/¾à»ç(2¸¸¿ø), Çлý-´ëÇÑ¿ø»ý Á¦¿Ü/º¸°Ç´ë/°£È£´ë/ÀÇ´ë(¹«·á)/65¼¼ ÀÌ»ó Á¤È¸¿ø(¹«·á) *ÇöÀåµî·Ï:ȸ¿ø(8¸¸¿ø),ºñȸ¿ø(10¸¸¿ø), Àü°øÀǹױâŸ(5¸¸¿ø), °£È£»ç/¿µ¾ç»ç/¾à»ç(2¸¸¿ø), Çлý-´ëÇÑ¿ø»ý Á¦¿Ü/º¸°Ç´ë/°£È£´ë/ÀÇ´ë(¹«·á)/65¼¼ ÀÌ»ó Á¤È¸¿ø(¹«·á)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-09 Room D 07:00~07:15 Management of stage 1 hypertension by AHA guideline with risk factor clustering Eugene Yang(USA,University of Washington School of Medicine)
±³À°½Ã°£ 11-09 Room D 07:15~07:30 Case presentation: prehypertension or grade 1 hypertension with risk factor clustering Á¤Çý¹®(°æÈñÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 07:30~07:45 Management of hypertension in very old patient Kazuomi Kario(Japan, Jichi Medical University School of Medicine)
±³À°½Ã°£ 11-09 Room D 07:45~08:00 Case presentation: very old hypertension patient Çã¶õ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 11-09 Room A 09:00~09:15 What is new in the 2018 Chinese Hypertension Guidelines? Jing Liu(China, Peking University People¡¯s Hospital)
±³À°½Ã°£ 11-09 Room A 09:15~09:30 Hypertension Guidelines Debate: Japanese Perspective Kazuomi Kario(Japan, Jichi Medical University School of Medicine)
±³À°½Ã°£ 11-09 Room A 09:30~09:45 Controversies over Defining Hypertension and its Blood Pressure Targets: time for Arteries to step in JK Cruickshank(UK, King¡¯s College London)
±³À°½Ã°£ 11-09 Room A 09:45~10:00 Asian perspectives in hypertension and cardiovascular protection Eugene Yang(USA,University of Washington School of Medicine)
±³À°½Ã°£ 11-09 Room A 10:00~10:15 Philipine perspectives in hypertension guidelines Nannette R. Rey(Philippine, De La Salle Medical and Health Sciences Institute)
±³À°½Ã°£ 11-09 Room A 10:15~10:30 Panel Discussion ½ÅÁøÈ£,±è±¤ÀÏ,ÀÓ»óÇö(ÇѾçÀÇ´ë,¼¿ïÀÇ´ë,°¡Å縯ÀÇ´ë)
ÈÞ½Ä 11-09 Park Ballroom 10:30~11:40 Moderated poster with coffee break ()
±³À°½Ã°£ 11-09 Room D 10:30~10:45 Day to day variability of Home BP and CVD ±è±¤ÀÏ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 10:45~11:00 Outcome researches of Home BP monitoring ȲÈñÁ¤(°æÈñÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 11:00~11:15 Targeting nocturnal HTN using Home BP monitoring ¹Ú»ó¹Î()
±³À°½Ã°£ 11-09 Room D 11:15~11:30 Application of home BP in CKD ÁöÁ¾Çö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-09 11:30~11:40 Panel Discussion À§Áø,ÃÖÀçÇõ,ÀÌ»óÀº(°¡ÃµÀÇ´ë,ÇѸ²ÀÇ´ë,ÀÌÈÀÇ´ë)
±³À°½Ã°£ 11-09 Room A,B,C 11:40~12:20 Role of ambulatory blood pressure monitoring in hypertension management Luis M. Ruilope(Spain, Autonoma University)
±³À°½Ã°£ 11-09 Room A,B,C 12:20~12:50 Genomics and precision medicine of hypertension and related vascular traits Norihiro Kato(Japan, National Center for Global Health and Medicine)
±³À°½Ã°£ 11-09 Room D 12:50~13:05 Options in using non-mercury device ¹Ú»ó¹Î(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 13:05~13:20 Clinical application of arterial function JK Cruickshank(UK, King¡¯s College London)
±³À°½Ã°£ 11-09 Room D 13:20~13:45 How to measure arterial stiffness ¹®Á¤±Ù(°¡ÃµÀÇ´ë)
ÈÞ½Ä 11-09 13:45~14:20 coffee break ()
±³À°½Ã°£ 11-09 Room A 14:20~14:35 °íÇ÷¾ÐÀÇ ¿øÀÎÀº ¹«¾ùÀÌ¸ç ¿Ö Áß¿äÇÑ°¡ ? ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-09 Room A 14:35~14:50 °íÇ÷¾Ð ½ÅȯÀ» Áø·áÇÒ ¶§ ¹Ýµå½Ã Æò°¡ÇؾßÇÏ´Â °ÍÀº ? ±è´ëÈñ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-09 Room A 14:50~15:05 out of office BP vs. office BP measurement ÀÓ»óÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-09 Room A 15:05~15:20 °íÇ÷¾ÐÀÇ Ä¡·á¸¦ ¾îµð±îÁö ÇؾßÇϴ°¡? Ä¡·á°¡ ÀßµÇ¸é ¾àÁ¦¸¦ ²÷À» ¼ö Àִ°¡? Á¶ÀºÁÖ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-09 Room A 15:20~15:30 Panel Discussion ÀÌÀº¹Ì,±è±¤ÀÏ,¹Ú¿ëÇö(¿ø±¤ÀÇ´ë,¼¿ïÀÇ´ë,ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 15:30~15:45 Epidemiologic perspectives of hypertension in heart failure ÇѼº¿ì(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 15:45~16:00 Intensive BP control, should it be considered for prevention of HF? ÀÌÁÖÈñ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 16:00~16:15 Anyone or someone, is there any difference in antihypertensive agents? ±è¿ëÇö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 16:15~16:30 SGLT2 inhibitor, can it prevent HF in hypertensive patients with diabetes? ±è¼ºÇØ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 11-09 Room D 16:30~16:45 Panel Discussion ÀÌ»óÀç,ÃÖ¼®¿ø,¼ÕÁ¤¿ì(¿ø±¤ÀÇ´ë,ÇѸ²ÀÇ´ë,¿¬¼¼¿øÁÖÀÇ´ë)